Edition:
United Kingdom

Abbvie Provides Update On Depatuxizumab Mafodotin (Depatux-M)


Friday, 17 May 2019 

May 17 (Reuters) - AbbVie Inc ::ABBVIE PROVIDES UPDATE ON DEPATUXIZUMAB MAFODOTIN (DEPATUX-M), AN INVESTIGATIONAL MEDICINE FOR NEWLY DIAGNOSED GLIOBLASTOMA, AN AGGRESSIVE FORM OF BRAIN CANCER.ABBVIE INC - PHASE 3 INTELLANCE-1 STUDY, CONDUCTED IN COLLABORATION WITH RTOG FOUNDATION, DID NOT MEET PRIMARY ENDPOINT OF OVERALL SURVIVAL.ABBVIE INC - PHASE 3 INTELLANCE-1 STUDY DEMONSTRATED NO SURVIVAL BENEFIT FOR PATIENTS RECEIVING DEPATUX-M.ABBVIE - INDEPENDENT DATA MONITORING COMMITTEE RESPONSIBLE FOR INTERIM ANALYSIS DATA REVIEW RECOMMENDED STOPPING STUDY DUE TO LACK OF SURVIVAL BENEFIT.ABBVIE INC - ENROLLMENT IN ALL ONGOING DEPATUX-M STUDIES HAS BEEN HALTED.ABBVIE INC - NO NEW SAFETY FINDINGS WERE OBSERVED ON DEPATUXIZUMAB MAFODOTIN.